Clinical Trial

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

Study acronym: REGOMAIN
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2026 (before its estimated July 21, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse. Patients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy after standard line therapy completion. Progression free rate (PFR) data will be collected and analysed for all included patients to evaluate if regorafenib + BSC can be considered as an interesting treatment for further investigations in this indication.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-01-05; most recent amendment 2026-02-13.
Status change: Not Yet Recruiting → Recruiting 2021-07-28
Trial Details
NCT Number NCT04698785
Lead Sponsor Centre Leon Berard
Conditions Bone Sarcoma, Osteosarcoma
Enrollment 36 participants
Start Date 2021-07-21
Primary Completion 2026-07-21 (estimated)
Study Completion 2026-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-02-17